<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Artificial intelligence-based personalized diet: A pilot clinical study for irritable bowel syndrome

dc.contributor.authorKarakan, Tarkan
dc.contributor.authorGundogdu, Aycan
dc.contributor.authorAlagozlu, Hakan
dc.contributor.authorEkmen, Nergiz
dc.contributor.authorOzgul, Seckin
dc.contributor.authorTunali, Varol
dc.contributor.authorNalbantoglu, O. Ufuk
dc.date.accessioned2026-10-09T21:49:18Z
dc.date.issued2022
dc.departmentYüksek İhtisas Üniversitesi
dc.description.abstractWe enrolled consecutive IBS-M patients (n = 25) according to Rome IV criteria. Fecal samples were obtained from all patients twice (pre-and post-intervention) and high-throughput 16S rRNA sequencing was performed. Six weeks of personalized nutrition diet (n = 14) for group 1 and a standard IBS diet (n = 11) for group 2 were followed. AI-based diet was designed based on optimizing a personalized nutritional strategy by an algorithm regarding individual gut microbiome features. The IBS-SSS evaluation for pre- and post-intervention exhibited significant improvement (p < .02 and p < .001 for the standard IBS diet and personalized nutrition groups, respectively). While the IBS-SSS evaluation changed to moderate from severe in 78% (11 out of 14) of the personalized nutrition group, no such change was observed in the standard IBS diet group. A statistically significant increase in the Faecalibacterium genus was observed in the personalized nutrition group (p = .04). Bacteroides and putatively probiotic genus Propionibacterium were increased in the personalized nutrition group. The change (delta) values in IBS-SSS scores (before-after) in personalized nutrition and standard IBS diet groups are significantly higher in the personalized nutrition group. AI-based personalized microbiome modulation through diet significantly improves IBS-related symptoms in patients with IBS-M. Further large-scale, randomized placebo-controlled trials with long-term follow-up (durability) are needed.
dc.identifier.doi10.1080/19490976.2022.2138672
dc.identifier.issn1949-0976
dc.identifier.issn1949-0984
dc.identifier.issue1
dc.identifier.orcid0000-0003-1561-8789
dc.identifier.orcid0000-0003-1799-2539
dc.identifier.orcid0000-0002-9184-2013
dc.identifier.pmid36318623
dc.identifier.scopus2-s2.0-85141181167
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1080/19490976.2022.2138672
dc.identifier.urihttps://hdl.handle.net/20.500.12794/3648
dc.identifier.volume14
dc.identifier.wosWOS:000877332200001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.digerScience Citation Index Expanded (SCI-EXPANDED)
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.ispartofGut Microbes
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260922
dc.subjectIrritable Bowel Syndrome
dc.subjectFunctional Gi Diseases
dc.subjectMicrobiome
dc.subjectSymptom Score Or Index
dc.subjectArtificial Intelligence
dc.subjectPersonalized Medicine
dc.titleArtificial intelligence-based personalized diet: A pilot clinical study for irritable bowel syndrome
dc.typeArticle

Files